Patents
Intellectual Property Rights (IPRs) as Core Assets
As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community. Innovation represents one of the strongest pillars of the company with more than 50 in-house scientists and a unique network of talented and renowned medical doctors contributing to Regen Lab’s Research & Development.
Over nearly 15 years, this innovation has been secured by building substantial patent & trademarks portfolios. Intellectual Property Rights (IPRs) therefore represent core assets of the company protecting its unique products and forging Regen Lab’s renowned brand names.
The patent portfolio can be divided into two core technologies:
1-PRP/BMC gel devices, methods and uses thereof, alone or in combination with cell extracts and associated key technologies like Autologous Thrombin Serum (ATS) and PRP Cell Culture.
Associated trademarks are REGENLAB®, REGENKIT®, REGENACR®, PRP®, A-PRP®, REGENCELL®, REGENPLASMA®, REGEN PRP®, REGEN®, REGEN EXTRACELL®, THT®, cellularmask®, CUTECELL®, REGENVET®, A-CPKIT® which are registered trademarks of REGEN LAB SA in Europe, United States and other countries.
2-Hyaluronic acid alone, cross-linked or not, or in combination with PRP/BMC leading to the unique “all in one” Cellular Matrix products combining in a synergetic manner the advantageous properties of PRP and HA, but also preparation in two separate devices.
Associated trademarks are REGENLAB®, REGENKIT®, CELLULAR MATRIX® fig., SKINVISC®, ARTHROVISC®, REGENMATRIX®, REGEN®, PRP® and A-PRP® which are registered trademarks of REGEN LAB in Europe, United States and other countries.
| Technology | Products / Trademarks | Patent(s) | Status | Expiration |
| A-PRPBone Marrow Concentrate (BMC)
Glue and membranes Combination with Cell Extracts Cell Culture |
RegenACR® RegenKit® Surgery RegenKit® BCT A-CP Kit® Regen Fibrin Polymer RegenKit® Extracell Regenwound™ Regen Extracell® Regencell® Regenplasma® THT® Cutecell® A-PRP® REGENPRP® REGEN® PRP® Regenvet® |
US11241458 US11110128 US11096966 US10881691 US10092598 US10080770 US10064894 US8529957 US9833478 US11241458 US11389482 US10052349 (PRP+HA) EP3395383B CH696752 HK1231793 |
Granted | 21.08.2027 21.08.2027 21.08.2027 21.08.2027 21.01.2028 21.08.2027 21.08.2027 07.03.2029 21.08.2027 21.08.2027 21.08.2027 21.08.2027 21.08.2027 27.04.2024 21.08.2027 |
| US2022313740 EP4137173 HK62023069504.6 WO2008/023026 WO2011/110948 WO2016/083549 WO2019/155391 |
Pending | 21.08.2027 21.08.2027 21.08.2027 21.08.2027 11.03.2031 26.11.2035 07.02.2039 |
||
| Autologous Thrombin Serum (ATS) alone
Combination with A-PRP for biological glues and membranes |
RegenKit® ATS Regenwound™ Regenkit Wound A-CP ATS Kit |
US10226516 EP3403659B AU2013203115B JP6359495 JP6588499 CA2915649 IL252122 KR10-2136314 IN330984 HK1179507 |
Granted | 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 |
| WO2011/110948 CN105998067 CN202211204780.2 RU2023102455 |
Pending | 11.03.2031 11.03.2031 11.03.2031 11.03.2031 |
||
| Combination therapy
A-PRP & Hyaluronic Acid |
ellular Matrix® fig. (linear HA) A-CP-HA |
US10272139 US8945537 US9517255 US10052349 EP2544697B1 EP3184114B EP2771241B CA2789533C JP6076091 JP6321119 JP6892485 AU2011225828B IL221133 RU2614722 RU2667964 KR20130067247 IN330984 HK1179507 US11077241 EP3223875B AU2015352458B EA035982B MA40376B IL252536 MX382517 UA123822 KR102362722B1 BR112017010837 BH1857-20220915 |
Granted | 11.03.2031 17.05.2031 11.03.2031 21.08.2027 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 11.03.2031 28.07.2037 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 |
| WO2011/110948 WO2013/061309 WO2019/155391 US2019201504 US2018327120 CN112220802 EP3854406 HK42021040392.9 HK40050052 CA2968731 CL20170001357 CN20158073651 CR20170000288 JP20180135503 KR20170088366 PE20170931 PH2017150094 SG20171104218P TN20170000220 US2018110917 AU2019218711 CA3089896 GCC2019/38117 EP3743079 JP2021515088 US2022193116 TW108128394 CN112118849 HK62020021959.5 KR10-2020-0130685 |
Pending | 11.03.2031 29.10.2032 07.02.2039 11.03.2031 29.10.2032 11.03.2031 11.03.2031 11.03.2031 11.03.2031 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 26.11.2035 28.07.2037 07.02.2039 07.02.2039 15.08.2039 07.02.2039 07.02.2039 07.02.2039 08.08.2039 07.02.2039 07.02.2039 07.02.2039 |
||
| Cellular Matrix Wound | IL284309 KR10-2521213 AU2021201102B2 |
Granted | 26.11.2035 26.11.2035 26.11.2035 |
|
| EP3903844 HK42021044735.5 US2021346587 WO2022/269035 GB2219505.1 |
Pending | 26.11.2035 26.11.2035 26.11.2035 26.06.2042 22.12.2042 |
||
| Viral infections (Covid 19) | RegenARP™ | WO2021/198312 CA3170584 AU2021249444 EP4114526 US 17/916,507 HK62023067606.1 |
Pending | 30.03.2041 30.03.2041 30.03.2041 30.03.2041 30.03.2041 30.03.2041 |
| N/A | Granted | N/A | ||
| Albumin-based bioresorbable cross-linked hydrogel | R&D | EP1543846B1 | Granted | 18.12.2023 |
V2023.2 May 22, 2023
Contact Regenlab
Now is the time to change your patient’s life. Browse ressources and
get connected to treatment that is right for them.
For more information on our products, please contact us by clicking on the button below:
Our Regional offices are
located in
- New York (USA)
- Montréal (Canada)
- Venice (Italy)
- Munich (Germany)
- Paris (France)
- Dubai (U.A.E.)
- Beijing (China)
- and Istanbul (Turkey)